The role of local geochemical and mineralogical backgrounds as essential information to build efficient sediment quality guidelines at high-mountainous hydrothermally-altered basins (Mapocho basin, Chile)

Autor: Correa-Burrows, José P., Navarrete-Calvo, Álvaro, Valenzuela-Díaz, Martín J., Zapata-Aguiló, Valeria A., Montserrat, Santiago, Navarro-Valdivia, Leonardo, McPhee, James, Caraballo, Manuel A.

Publikováno v: In Science of the Total Environment 1 September 2021 785

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice

Autor: Gao, L., Díaz-Martín, J., Dillmann, W.H., López-Barneo, J.

Publikováno v: In Neuroscience 2011 193:323-329

Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness.

Autor: Sonzini G; Department of Pathology, Medical School, University of Valencia-INCLIVA, Valencia, Spain., Granados-Aparici S; Department of Pathology, Medical School, University of Valencia-INCLIVA, Valencia, Spain., Sanegre S; Department of Pathology, Medical School, University of Valencia-INCLIVA, Valencia, Spain.; 2 Cancer CIBER (CIBERONC), Madrid, Spain., Diaz-Lagares A; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain., Diaz-Martin J; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla, Seville, Spain., de Andrea C; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Eritja N; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Institut de Recerca Biomèdica de LLeida (IRBLLEIDA), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Department of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, University of Lleida - University of Barcelona, Barcelona, Spain., Bao-Caamano A; Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.; Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain., Costa-Fraga N; Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.; Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain., García-Ros D; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Salguero-Aranda C; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla, Seville, Spain., Davidson B; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway., López-López R; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Melero I; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Navarro S; Department of Pathology, Medical School, University of Valencia-INCLIVA, Valencia, Spain.; 2 Cancer CIBER (CIBERONC), Madrid, Spain., Ramon Y Cajal S; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Department of Pathology, Vall d'Hebron University Hospital, Autonoma University of Barcelona, Barcelona, Spain., de Alava E; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla, Seville, Spain., Matias-Guiu X; 2 Cancer CIBER (CIBERONC), Madrid, Spain.; Institut de Recerca Biomèdica de LLeida (IRBLLEIDA), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Department of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, University of Lleida - University of Barcelona, Barcelona, Spain., Noguera R; Department of Pathology, Medical School, University of Valencia-INCLIVA, Valencia, Spain.; 2 Cancer CIBER (CIBERONC), Madrid, Spain.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2022 Nov 18; Vol. 10, pp. 1052098. Date of Electronic Publication: 2022 Nov 18 (Print Publication: 2022).

Excess weight in patients with cystic fibrosis: is it always beneficial?

Autor: Gonzalez-Jimenez D, Munoz-Codoceo R, Garriga-Garcia M, Molina-Arias M, Alvarez-Beltran M, Garcia-Romero R, Martinez-Costa C, Meavilla-Olivas S, Pena-Quintana L, Gallego-Gutierrez S, Marugan-de-Miguelsanz J, Suarez-Cortina L, Castejon-Ponce E, Leis-Trabazo R, Martin-Cruz F, Diaz-Martin J, Bousono-Garcia C

Publikováno v: Nutricion Hospitalaria
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::224ae651f0c7441609f83eb804b8ea52
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2877